Novo Nordisk (NVO) Reports Q2 EPS of DKK10.17; raises outlook

Novo Nordisk (NYSE: NVO) reported Q2 EPS of DKK10.17. Revenue for the quarter came in at DKK133.41 billion.

OUTLOOK

For the 2024 outlook, sales growth is now expected to be 22-28% at CER, and operating profit growth is now expected to be 20-28% at CER. Growth reported in Danish kroner is now expected to be 1 percentage point lower than at CER growth for both sales and operating profit.

For earnings history and earnings-related data on Novo Nordisk (NVO) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Baker Hughes wins long-term service deal for Nigeria gas plant
• Winnebago Industries (WGO) PT Lowered to $40 at Benchmark on Pressured NT Demand